MRI-Compatible Neural Implant Patent Snapshot 2026
MRI-compatible neural implant patenting is a nascent, highly concentrated field dominated by a small cluster of U.S. academic and specialist medical-device institutions, with the top five filers collectively accounting for the entire visible corpus. Activity has plateaued, suggesting the space is entering a maturity phase where foundational positions are held but commercialization pathways remain open.
Five equal-share filers dominate a tightly held niche
The University of Southern California, Advanced Neuromodulation Systems Inc., Genesis Intelligence LLC, the Board of Regents of the University of Texas System, and William Marsh Rice University each hold equal positions at the top of the applicant ranking, with no single organization holding a commanding lead.
The top five filers account for the entire share of the ranked applicants visible in this query, underscoring an extremely concentrated field with no mid-tier challenger layer yet visible. The absence of large medical-device conglomerates in the ranking is a structurally notable feature.
| # | Applicant | Patent records | Share |
|---|---|---|---|
| 1 | University of Southern California | 2 | |
| 2 | Advanced Neuromodulation Systems Inc. | 2 | |
| 3 | Genesis Intelligence LLC | 2 | |
| 4 | Board of Regents, The University of Texas System | 2 | |
| 5 | William Marsh Rice University | 2 |
Academic institutions hold at least three of the five leading positions, implying that foundational IP is still being established in university labs rather than corporate R&D centers — a pattern consistent with a technology still transitioning from bench research toward commercial development.
Patent records published within the most recent 18–24 months are subject to publication lag and may undercount actual filing activity; the apparent plateau in the latest period should be interpreted with that caveat. Longer-window growth, applicant concentration, and technology-route coverage are therefore more reliable signals than the latest-year bar alone.
Episodic filings and an electrotherapy-dominated technology mix
Annual filing activity has been sparse and episodic since 2017, clustering into a few discrete bursts rather than a sustained upward curve. The technology composition is heavily skewed toward electrotherapy and radiation therapy, with fluid-delivery device classes appearing as a secondary branch.
Annual filing trend
Filings appear in isolated years — 2019, 2024, and 2026 — with zero activity in several intervening years, reflecting the niche nature of the topic. The most recent data points (2024–2026) are subject to publication lag and should not be read as a trend signal without further monitoring.
↗ Hover for values · click a bar to ask EurekaTechnology composition
The A61N electrotherapy and radiation therapy class accounts for the visible share of patent records, with A61M devices for body fluids providing a secondary but meaningful presence. This split maps onto two distinct device architectures: direct-stimulation implants and catheter-based delivery systems designed to remain safe under MRI scanning.
↗ Hover for values · click a bar to ask EurekaHighly cited patent families surfaced by the query
Citation-heavy patent families returned by the query. Use this section as citation context, not as a curated list of the most topic-specific patents.
Kinetic intelligent wireless implant
Embodiments of an implantable system and apparatus for providing electrical and optical deep brain stimulation are disclosed. Through the biological introduction of light-responsive opsins to neurons, the system is operable to transform neurons into optogenetically programmable state and history-dependent logical transformers. Embedded processors of the… (excerpt from the patent abstract)
| # | Patent | Citations |
|---|---|---|
| 1 | Cortical subarachnoid and intraventricular brain i… | 8 |
| 2 | Leads for neurostimulation and method of assemblin… | 5 |
| 3 | Closed-loop multi-channel asynchronous neurostimul… | 4 |
| 4 | Leads for neurostimulation and method of assemblin… | 1 |
Ranked by total forward citations. Citation counts favour older and broadly cited patent families, and broad or adjacent patents may appear when they match the search scope. Treat this section as citation context, not as a curated list of the most topic-specific patents. Some patent titles may be shown in their original, non-English language where an accurate translation could not be guaranteed.
Assignee snapshot from the current evidence set
The applicants below are visible in this query result. Because the evidence set is relatively small, read this section as a directional snapshot rather than a full competitive ranking.
University of Southern California
USC holds 2 patent records focused entirely on A61N electrotherapy and radiation therapy, establishing it as a foundational contributor to the direct-stimulation architecture of MRI-compatible neural implants. As one of the earliest filers in the corpus, USC’s position is anchored in core device design rather than peripheral methods. No momentum data is available for this applicant, so recent trajectory is evidence pending.
patent records: 2University of Texas System & Rice University
Both the Board of Regents of the University of Texas System and William Marsh Rice University hold 2 patent records each and are identified as new entrants with upward momentum. Their technology focus spans both A61M fluid-delivery devices and A61N electrotherapy, giving them the broadest dual-class coverage among all filers. Their documented co-filing relationship suggests this output reflects a coordinated joint program rather than independent parallel work.
patent records: 2 eachFrequently asked questions
The current corpus contains 7 patent families in scope. This is a small, specialized corpus reflecting the niche intersection of MRI safety engineering and neural implant design.
The University of Southern California, Advanced Neuromodulation Systems Inc., Genesis Intelligence LLC, the Board of Regents of the University of Texas System, and William Marsh Rice University are all tied at the top of the applicant ranking, each holding 2 patent records.
The lifecycle evidence indicates the field has plateaued near its peak annual volume. Filing activity has been episodic rather than continuous, and the most recent 18–24 months of data may be undercounted due to publication lag, so the current state should be monitored before drawing conclusions about long-term trajectory.
All patent records in the corpus are filed in the United States. No equivalent filings have been identified in European, Asian, or other major patent jurisdictions, leaving significant international territory uncontested.
Yes. The Board of Regents of the University of Texas System and William Marsh Rice University have co-filed 2 patent records, making them the only documented co-filing pair in the corpus. This likely reflects a coordinated joint research program within the Houston academic corridor.
The visible class is A61N, covering electrotherapy and radiation therapy devices, which accounts for the majority of patent records. A secondary presence exists in A61M, covering devices for body fluids, concentrated in the University of Texas / Rice University collaboration.
Ready to map your own MRI-compatible neural implant Snapshot?
Join 18,000+ innovators using PatSnap Eureka to map any technology landscape: search 2B+ patents and papers, surface key assignees, and generate a report like this in minutes.
Disclaimer. This page is generated from PatSnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. PatSnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.